Cerevel Therapeutics

Summary

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

History

Cerevel Therapeutics was founded in 2019 as a collaboration between Allergan, AbbVie, The Fernwood Foundation, and Frazier Healthcare Partners. Through this partnership, the company seeks to develop therapies for community and rare neurological disorders.

Mission

Cerevel Therapeutics is committed to developing medicines to treat community and rare neurological disorders, including but not limited to Alzheimer's disease, Parkinson's disease and Primary Progressive Aphasia.

Vision

At Cerevel, we envision a world where those suffering from neurological disorders can live lives that are rich, meaningful, and without limitation.

References

https://in.investing.com/equities/arya-sciences-acquisition-ii

https://finance.yahoo.com/quote/CERE/profile?p=CERE

https://www.crunchbase.com/organization/cerevel-therapeutics

https://sec.report/CIK/0001805387

https://companiesmarketcap.com/

https://www.cerevel.com

Cerevel Therapeutics

Share

Contacts

Follow Us

Cerevel Therapeutics

Share

Contacts

Follow Us